Quantcast
Last updated on April 21, 2014 at 12:39 EDT

Latest Cisplatin Stories

2009-03-11 07:26:01

Breast cancer patients face many horrors, including those that arise when fighting the cancer itself. Medications given during chemotherapy can have wicked side effects, including vomiting, dizziness, anemia and hair loss. These side effects occur because medications released into the body target healthy cells as well as tumor cells.The trick becomes how to deliver cancer-fighting drugs directly to the tumor cells. Brown University chemists think they have an answer: They have created a twin...

2009-01-13 13:05:13

For years, research has hinted that the time of day that cancer patients receive chemotherapy can impact their chances of survival. But the lack of a clear scientific explanation for this finding has kept clinicians from considering timing as a factor in treatment. Now, a new study from the University of North Carolina at Chapel Hill has suggested that treatment is most effective at certain times of day because that is when a particular enzyme system "“ one that can reverse the actions...

2008-12-09 19:18:24

A precious metal never used in a clinical setting is being developed as a next-generation cancer treatment, British researchers report. University of Warwick researchers are working with the metal, osmium, which is related to platinum and is used to treat cancers as part of the drug cisplatin, the university said in a news release. The Department of Chemistry researchers are seeking partners to help develop osmium through more extensive biological tests. While cisplatin is successful...

2008-11-20 15:22:40

Phosphaplatins can effectively kill ovarian, testicular, head and neck cancer cells with potentially less toxicity than other drugs, U.S. researchers said. The new class of compounds could be less harmful than current cancer treatments on the market such as cisplatin and carboplatin because they don't penetrate the cell nucleus and attach to DNA, said lead author Rathindra Bose, who conducted the work while at Northern Illinois University. Conventional drugs can interfere with the functions...

da9126d890b38d451756da92445705ec1
2008-11-20 09:11:42

Agents bind to different targets than conventional drugs A new class of compounds called phosphaplatins can effectively kill ovarian, testicular, head and neck cancer cells with potentially less toxicity than conventional drugs, according to a new study published this week in the journal Proceedings of the National Academy of Sciences. The compounds could be less harmful than current cancer treatments on the market such as cisplatin and carboplatin because they don't penetrate the cell...

2008-11-14 09:00:34

CALGARY, Nov. 14 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that a poster presentation authored by Dr. Anders Kolb of the Nemours Center for Childhood Cancer Research entitled "Systemic Administration of REOLYSIN Inhibits Growth of Human Sarcoma Xenografts Alone and in Combination with Cisplatin and Radiation" is scheduled to be presented today at the 14th Annual Meeting of the Connective Tissue Oncology Society (CTOS). The meeting is being...

2008-10-02 12:06:58

Alimta has received US approval for use as a first-line therapy in locally advanced and metastatic non-small cell lung cancer in combination with cisplatin. This third FDA approval for Alimta follows its prominent use in patients with non-squamous carcinoma cell histology and highlights the shift towards a more tailored approach for lung cancer therapy. Alimta (pemetrexed) received US approval as a first-line therapy for locally advanced and metastatic non-small cell lung cancer (NSCLC)...

2008-09-30 09:45:00

Eli Lilly and Company has received approval from the FDA for the use of Alimta in combination with cisplatin, in the first-line treatment of locally-advanced and metastatic non-small cell lung cancer, for patients with nonsquamous histology. This marks the third US indication for Alimta. In 2004, Alimta has received consecutive approvals: first in combination with cisplatin as a treatment for patients with malignant pleural mesothelioma, whose disease is unresectable or who are otherwise not...

2008-09-29 09:00:14

INDIANAPOLIS, Sept. 29 /PRNewswire-FirstCall/ -- Eli Lilly and Company announced today it received approval from the U.S. Food and Drug Administration (FDA) for the use of ALIMTA(R) (pemetrexed for injection), in combination with cisplatin, in the first-line treatment of locally-advanced and metastatic non-small cell lung cancer (NSCLC), for patients with nonsquamous histology. ALIMTA is not indicated for treatment of patients with squamous cell non-small cell lung cancer. NSCLC is the...

2008-08-29 00:00:36

U.S. researchers say they have linked a genetic variant of a protein to resistance to the chemotherapy drug cisplatin. The University of California, San Diego, researchers found that when a specific variant form of PMS2 -- a cell repair protein that fixes DNA mistakes and plays a role in cell death -- is active, cisplatin doesn't kill cancer cells the way it normally does. In experiments using mouse cells, the researchers, led by Jean Wang and Richard Kolodner, found PMS2 normally...